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JPET #236000 INTRODUCTION
Modafinil (MOD; Provigil®) exhibits therapeutic efficacy for treating a variety of neuropathologies, including sleep-related disorders such as narcolepsy (Wise, et al., 2007) , obstructive sleep apnea syndrome (Pack, et al., 2001) , and shift-work sleep disorder (Czeisler, et al., 2005) , attention deficit hyperactivity disorder (ADHD) (Swanson, et al., 2006) , and drug addiction (Anderson, et al., 2009; Shearer, et al., 2009 ; but see Anderson, et al., 2012) . Similar to other psychostimulants used therapeutically, such as amphetamine (Adderall®) and methylphenidate (Ritalin®), MOD enhances locomotor activity (Kuczenski, et al., 1991; Edgar and Seidel, 1997; Kuczenski and Segal, 2001) , wakefulness (Wisor, et al., 2001; Ishizuka, et al., 2008) , and cognitive ability (Barch and Carter, 2005; Kumar, 2008; Repantis, et al., 2010) .
Indeed, a recent meta-analysis study has concluded that MOD can be safely used as a cognitive enhancer in healthy subjects (Battleday and Brem, 2015) . Moreover, unlike other therapeutic psychostimulants, MOD exhibits limited potential for abuse (Deroche-Gamonet, et al., 2002) .
These attractive psychostimulant characteristics have thus generated considerable interest in establishing the neuropharmacologic mechanism of MOD action.
Although MOD has been found to alter various neurotransmitter systems in the brain, including those for histamine, hypocretin (orexin), GABA, glutamate, norepinephrine, and serotonin, its effects on midbrain dopamine (DA) systems have received the greatest attention (Tanganelli, et al., 1992; Ferraro, et al., 1997; Chemelli, et al., 1999; de Saint, et al., 2001; Ishizuka, et al., 2003) . This atypical psychostimulant preferentially interacts with the dopamine transporter (DAT), compared to transporters for other monoamines such as norepinephrine and serotonin, and shows little affinity for receptors of monoamines and other neurotransmitters (Mignot, et al., 1994; Madras, et al., 2006; Zolkowska, et al., 2009 ). However, whether MOD This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on October 12, 2016 as DOI: 10.1124 at ASPET Journals on October 18, 2017 jpet.aspetjournals.org Downloaded from JPET #236000 5 acts directly through DAT remains highly controversial. On the one hand, MOD exhibits weak affinity for DAT (Mignot, et al., 1994; Madras, et al., 2006; Zolkowska, et al., 2009 ) and elicits only relatively modest increases in striatal dialysate DA (Ferraro, et al., 1997; Loland, et al., 2012) . On the other hand, MOD's effects appear to rely on DAT, as MOD-induced wakefulness is abolished in DAT-knockout mice (Wisor, et al., 2001 ).
Based on work investigating actions of other DAT-inhibiting psychostimulants, another potential target for MOD is phasic DA signaling. DA neurons signal in two distinct modes, with slow, irregular firing of DA neurons generating a basal level of extracellular DA called tone during tonic DA signaling and burst firing of DA neurons generating rapid increases in extracellular DA called transients during phasic DA signaling (Grace and Bunney, 1984) .
Substantive evidence implicates a critical role played by phasic DA signaling in reward learning (Schultz, et al., 1997; Day, et al., 2007) and seeking (Phillips, et al., 2003) , and alterations in phasic DA signaling are hypothesized to contribute to ADHD (Tripp and Wickens, 2008) and drug abuse (Covey, et al., 2014) . DAT-inhibiting psychostimulants have also been shown to activate phasic DA signaling by increasing burst firing of DA neurons (Shi, et al., 2000; Shi, et al., 2004; Koulchitsky, et al., 2012) and the frequency of DA transients in the striatum (Venton and Wightman, 2007; Covey, et al., 2013; Daberkow, et al., 2013) , and by presynaptically enhancing DA release, in addition to inhibiting DA uptake (Wu, et al., 2001a; Venton, et al., 2006; Chadchankar, et al., 2012) . Whether MOD acts similarly to activate phasic DA signaling has not been examined.
Here we use fast-scan cyclic voltammetry (FSCV) at a carbon-fiber microelectrode (CFM) to investigate the effects of MOD on phasic DA signaling in urethane-anesthetized rats.
The effects of MOD were examined in dorsal and ventral striata across a wide behaviorally This article has not been copyedited and formatted. The final version may differ from this version. 
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6 relevant range of doses (30 -300 mg/kg i.p.), based on effects on cognitive function, locomotion, and wakefulness (Edgar and Seidel, 1997; Beracochea, et al., 2001; Ward, et al., 2004) . Two measures of phasic DA signaling were assessed: the amplitude of electrically evoked phasic-like DA signals (Avelar, et al., 2013) and the frequency of DA transients elicited in the presence of the D2 DA antagonist, raclopride, (Venton and Wightman, 2007) . DA transients were determined from non-electrically evoked DA traces processed by principal component regression (PCR) (Keithley, et al., 2009 ). In addition, the effects of MOD on the presynaptic mechanisms of DA release and uptake (Wu, et al., 2001b ) and on basal DA levels processed by PCR were examined. Taken together, our results suggest that activation of phasic DA signaling is a novel mechanism contributing to the therapeutic efficacy of MOD.
8 60 min post-drug. The effects of vehicle or high-dose MOD (300 mg/kg) on changes in basal DA were examined pre-drug and for 40 min post-drug. In the second experimental design, electrical stimulation was applied pre-drug and every 30 min post-drug to assess the veracity of the CFM.
After pre-drug recordings, raclopride (2 mg/kg) was co-administered with low-dose MOD (30 mg/kg), and DA transients were analyzed during 5-min epochs pre-drug and post-drug at 15, 30, 60 and 120 min. All vehicle and drugs were administered intraperitoneally (i.p.) in a total volume of 2 ml. n = 4-7 each in the dorsal and ventral striatum.
Electrochemistry. DA measurements were recorded with FSCV by applying a triangular waveform (-0.4 to +1.3V and back) to the CFM at a rate of 400V/s every 100 ms. CFMs were fabricated by aspirating a single carbon fiber (r=3.55 µm; HexTow AS4, HexCel Corp., Stamford, CT, USA) into a borosilicate capillary tube (1.2mm o.d.; Sutter Instrument, Novato, CA, USA) and pulling to a taper using a micropipette puller (Narishige, Tokyo, Japan). The carbon fiber was then cut to ~100 µm distal to the glass seal. FSCV was performed by a Universal Electrochemistry Instrument (UEI; Department of Chemistry Electronic Shop, University of North Carolina, Chapel Hill, NC, USA) and commercially available software (ESA Bioscience, Chelmsford, MA, USA). Current recorded at peak oxidative potential for DA (~+0.6 V) was converted to DA concentration based on post-calibration of the CFM using flowinjection analysis in a modified TRIS buffer (Kume-Kick and Rice, 1998; Wu, et al., 2001b) . DA was identified by the background subtracted voltammogram (Michael, et al., 1998; Heien, et al., 2004) . In experiments assessing effects of MOD on basal DA and DA transients, DA was additionally identified using PCR (see below).
Electrical stimulation. Electrical stimulation was computer generated and passed through an optical isolator and constant-current generator (Neurolog NL800; Digitimer Limited, Letchworth This article has not been copyedited and formatted. The final version may differ from this version. (Wightman, et al., 1988; Wu, et al., 2001b) :
where [DA] p is the concentration of DA elicited per stimulus pulse and is used to index DA release, k is the first-order rate constant describing DA uptake, and f is the frequency of electrical stimulation.
[DA] p and k were determined by fitting electrically evoked DA signals to Equation 1
using nonlinear regression with a simplex-minimization algorithm (Wu, et al., 2001b) . Temporal distortion in measured DA responses was accounted for using a diffusion gap model, with the gap width held constant for each CFM across pre-and post-drug measurements (Wu, et al., 2001b ).
Analysis of basal DA and DA transients. Changes in DA during non-electrically evoked recording were assessed using PCR to resolve DA, pH, and background drift from raw FSCV recordings (Hermans, et al., 2008; Keithley, et al., 2009 
MOD increases DA release and decreases DA uptake
This article has not been copyedited and formatted. The final version may differ from this version. MOD-induced increases in [DA] max could be mediated by enhanced DA release and/or inhibited DA uptake. To initially assess whether MOD decreased DA uptake, electrically-evoked decay curves were overlaid beginning at the same concentration (Fig. 3, inset) , and the slopes were visually inspected between pre-and post-drug traces. The downward slope of the evoked trace is thought to reflect DA uptake and not DA release (Wu, et al., 2001b) . Thus, the flatter post-drug traces after MOD indicate slower DA extracellular clearance (Fig. 3 ). This qualitative approach suggests that MOD decreases DA uptake and that the increase in [DA] max may be due to DA uptake inhibition, at least in part. However, MOD-induced increases in DA release may also play a role, because the upward slope of the evoked trace reflects the balance of both DA release and uptake (Wu, et al., 2001b) . (Wu, et al., 2001b) . We therefore used path analysis to directly evaluate the respective contribution of these two presynaptic mechanisms to the dose-dependent effects of MOD on [DA] max . Path analysis (Mitchell RJ, 1998 ) is a statistical technique that tests effects of multiple independent variables on a dependent variable, much like multiple regression; however, path analysis allows for the possibility that variables can be both dependent and independent (i.e., variables can be both affected by MOD and affect other variables; (Fig. 5) . For DA release this product is 0.5570, whereas for DA uptake this product is 0.1089. Thus, the indirect effect via DA release is more than 5 times greater than that via DA uptake, indicating that MOD-induced increases in
[DA] max are primarily mediated via increased DA release.
Alternative path models (i.e., omitting either effects of DA release or uptake on [DA] max from the full model) were conducted, and AIC values, an indicator of information lost by using models to describe data (Anderson, 2008) , were compared to determine which model was most appropriate. Omitting effects of DA release or uptake resulted in increased AIC (109.5 and 23.4 This article has not been copyedited and formatted. The final version may differ from this version. 
MOD and basal DA
MOD effects on basal DA were assessed by applying a chemometrics analysis called PCR (Hermans, et al., 2008; Keithley, et al., 2009) The lack of significant effect of MOD on basal DA assessed by PCR opposes previous findings demonstrating increases in dialysate DA at the same dose (Ferraro, et al., 1997; Loland, et al., 2012) . To address the concern that PCR assigned a portion of the DA signal to a non-DA principal component and that this misplaced DA led to the inability to detect an increase in basal 
MOD activates DA transients
This article has not been copyedited and formatted. The final version may differ from this version. Co-administration of a DA D2 receptor antagonist with a DAT-inhibiting psychostimulant elicits DA transients in urethane-anesthetized rats, without affecting these phasic signals when administered alone (Venton and Wightman, 2007; Park, et al., 2010) . Presumably, the DA D2 receptor antagonist in the anesthetized preparation prevents the psychostimulant-induced autoinhibition of DA neurons but reveals the psychostimulant-induced activation of burst firing by DA neurons (Shi, et al., 2000; Shi, et al., 2004) . In contrast, psychostimulant-induced activation of DA cell burst firing (Koulchitsky, et al., 2012) and DA transients (Stuber, et al., 2005; Aragona, et al., 2008; Daberkow, et al., 2013) 
DISCUSSION
Here we demonstrate that MOD activates phasic DA signaling in dorsal and ventral striata.
Activation was indicated by increased amplitude of electrically evoked phasic-like DA signals, enhanced DA release, inhibited DA uptake, and increased frequency of DA transients. Taken together, these results suggest that activation of phasic DA signaling is a novel mechanism contributing to the therapeutic efficacy of MOD.
MOD and basal DA
PCR was used to investigate the effects of MOD on basal DA. This approach revealed no significant changes in basal DA in either dorsal or ventral striata with the highest dose of MOD tested (300 mg/kg). In contrast, an ≈ 3-fold elevation in striatal dialysate DA has been reported for the same dose (Ferraro, et al., 1997; Loland, et al., 2012) . The determination of basal DA is analytically difficult (Sandberg and Garris, 2010) , and this discrepancy could be attributed to differences in the two monitoring techniques, which are not fully understood. The use of FSCV coupled to PCR for monitoring basal DA is also an emerging approach. While we demonstrated that PCR was not incorrectly assigning DA to a non-DA principal component in electrically evoked DA signals, the DA concentrations analyzed were much greater than the non-significant changes detected in basal DA and recent estimates of basal DA of ≈ 100 nM (Atcherley, et al., 2015) . However, PCR has previously detected both increases and decreases in DA levels within these non-significant concentration changes and well below 100 nM (≈5 to 40 nM; Hart, et al., 2014; Roitman et al., 2008) . Thus, although PCR appears to have the requisite sensitivity to detect a change in basal DA, a definitive determination of whether MOD acts on basal DA requires further study.
MOD activates phasic DA signaling via effects at DA terminals
This article has not been copyedited and formatted. The final version may differ from this version. Consistent with other DAT-inhibiting psychostimulants, such as cocaine, amphetamine, and methylphenidate (Venton, et al., 2006; Ramsson, et al., 2011b; Chadchankar, et al., 2012; Covey, et al., 2013; Avelar, et al., 2013; Daberkow, et al., 2013) , we show that MOD increases DA release and inhibits DA uptake. Thus, our results support the notion that DAT-inhibiting psychostimulants share a common action of altering both presynaptic mechanisms (Covey, et al., 2014) . How MOD increases DA release is not known. Cocaine and methylphenidate increase DA release via actions on synaptic proteins such as synapsin and α -synuclein, respectively (Chadchankar, et al., 2012; Venton, et al., 2006) , whereas amphetamine increases DA release by inhibiting DA degradation and increasing DA synthesis (Avelar, et al., 2013) . Further work is needed to determine whether MOD increases DA release by these or other mechanisms.
Because the upward slope of the electrically evoked DA signal reflects the balance between DA release and uptake (Wightman, et al., 1988) , both presynaptic mechanisms could mediate the observed MOD-induced increases in [DA] max . While indirect evidence suggests that enhanced DA release, as compared to inhibited DA uptake, is more responsible for increases in
[DA] max elicited by other psychostimulants (Venton, et al., 2006; Avelar, et al., 2013; Covey, et al., 2013; Daberkow, et al., 2013) , this hypothesis has never been directly tested as we do here.
Indeed, path analysis indicated that MOD-induced increases in [DA] max are more strongly mediated by enhanced DA release. The relative contributions of DA release and uptake to
[DA] max may inform alterations of DA transients by DAT-inhibiting psychostimulants. For example, while it is thought that increased burst firing of DA neurons drives increased transient frequency and inhibited DA uptake drives increased transient duration, the mechanism underlying increased transient amplitude is debated (Covey, et al., 2014) . Our results suggest that enhanced DA release, not inhibited DA uptake, is primarily responsible for the increased This article has not been copyedited and formatted. The final version may differ from this version. 
JPET #236000
2 0 transient amplitude with DAT-inhibiting psychostimulants. However, caution is urged because this conclusion assumes that the parameters for DA release and uptake obtained from electrically evoked phasic-liked DA signals relate to DA transients, and this assumption has been difficult to test.
MOD activates DA transients
We investigated the ability of MOD to elicit DA transients in urethane-anesthetized rats when co-administered with the DA D2 antagonist, raclopride. Our findings show that MOD, a lowaffinity DAT inhibitor, elicited DA transients in both dorsal and ventral striata at the lowest dose tested (30 mg/kg) when co-administered with raclopride. While MOD increasing the frequency of DA transients is consistent with eliciting burst firing of DA neurons (Covey, et al., 2014) , the combination of MOD and raclopride could additionally have increased the amplitude of spontaneously occurring (i.e., ongoing) transients above the FSCV detection limit, which may also have contributed to the observed frequency increase. Interestingly, the frequency of DA transients elicited by MOD was similar to that elicited by a high-affinity DAT inhibitor, nomifensine, under similar conditions (Venton and Wightman, 2007) , suggesting that the MODinduced activation is robust. Unfortunately, quantitatively comparing this MOD effect to the psychostimulant-induced activation of DA transients observed in awake rats (Venton and Wightman, 2007; Covey, et al., 2013; Daberkow, et al., 2013) is tenuous, because the use of ralcopride in the present experiment, particularly its blockade of somatodendritic DA autoreceptors, is confounding in isolating the specific effects of MOD. Another potential concern in interpreting the observed MOD-induced activation of DA transients is the profound effects of anesthetics on DA neuron firing (Chiodo, 1988; Kelland, et al., 1990) . Thus, there is a great need This article has not been copyedited and formatted. The final version may differ from this version. to establish the MOD-induced activation of DA transients in awake animals and in the absence of raclopride.
Addictive nature of psychostimulants
A long-held view in addiction research is that, despite diverse cellular actions, all abused drugs increase brain extracellular DA, with a preferential action in ventral compared to dorsal striata (Di Chiara and Imperato, 1988) . More recent work has refined this view by hypothesizing that abused drugs excessively activate phasic DA signaling (Covey, et al., 2014) , leading to the hijacking of reward circuits and aberrant reward learning (Hyman, et al., 2006) . While cocaine and amphetamine conform to this hypothesis (Venton and Wightman, 2007; Covey, et al., 2013; Daberkow, et al., 2013) , other mechanisms have been proposed to explain differences in abuse potential for DAT-inhibiting psychostimulants, including DAT affinity (Ritz, et al., 1987) , speed of brain drug action (Yorgason, et al., 2011) , and actions via DAT mimicking G protein-coupled receptors, i.e., via the so-called "transceptor" (Schmitt, et al., 2013) . Because MOD increases electrically evoked DA levels in the dorsal striatum to a greater extent than in the ventral striatum, it is interesting to speculate that MOD targeting DA signaling in the dorsal striatum contributes to its limited abuse potential (Deroche-Gamonet, et al., 2002) .
The basis for differential effects of DAT-inhibiting psychostimulants in striatal subregions is not known. Heterogeneity of DA neurons innervating the dorsal and ventral striatum (Doucet, et al., 1986; Marshall, et al., 1990; Lammel, et al., 2008 ) favors a similar sub-regional specificity in drug effects, which is not the case. Thus, other factors must be involved. DAT is a potential mediator, and different classes of DAT-inhibitors bind to different sites on DAT (Loland, et al., 2012; Schmitt, et al., 2013) . Not unexpectedly, DAT-inhibiting psychostimulants differentially inhibit DA uptake in the striatal sub-regions, but these effects appear unrelated to This article has not been copyedited and formatted. The final version may differ from this version. abuse potential (present study; Jones, et al., 1995; Wu, et al., 2001a; Ramsson, et al., 2011a) . DA release is another potential mediator, but much less is known about the effects of psychostimulants on this presynaptic mechanism. Clearly, more work is needed to identify the cellular mechanisms distinguishing the differential effects of DAT-inhibiting psychostimulants in the striatum and whether this differential activation involves DA transients.
Clinical efficacy of MOD
It is interesting to speculate that activation of phasic DA signaling as demonstrated herein contributes to the clinical efficacy of MOD. For example, therapeutic for ADHD (Swanson, et al., 2006) , MOD may be targeting the insufficient phasic DA signaling proposed to underlie deficits in reward learning observed with this neurodevelopmental pathology (Tripp and Wickens, 2008) . A similar activation of phasic DA signaling, albeit from normal levels, may mediate MOD-enhanced cognitive ability in healthy subjects (Muller, et al., 2013) . Moreover, L-DOPA has been shown to restore the amplitude of DA transients reduced by long-access cocaine self-administration (Willuhn, et al., 2014) , and MOD may be acting similarly in psychostimulant abusers (Anderson, et al., 2009; Shearer, et al., 2009 ). Finally, while roles for serotonin, norepinephrine, and acetylcholine are well established in sleep-wakefulness (Pace-Schott and Hobson, 2002), more recent evidence implicates DA (Wisor, et al., 2001; Dahan, et al., 2007) and perhaps phasic DA signaling (Dahan, et al., 2007) . Consistent with activation of phasic DA signaling as reported herein, MOD-induced wakefulness is dependent on DA receptors (Qu, et al., 2008) and an intact striatum (Qiu, et al., 2012) .
Conclusions
We found that MOD increases the frequency of DA transients, enhances DA release, and inhibits DA uptake in dorsal and ventral striata. Based on these measurements, we propose a mechanism This article has not been copyedited and formatted. The final version may differ from this version. 
